Valuation: 2cureX AB

Market Cap 7.43M 765K 670K 618K 577K 1.09M 72.32M 1.11M 2.87M 35.7M 2.87M 2.81M 125M P/E 2022
-4.81x
P/E 2023 -1.09x
Enterprise Value -5.97M -615K -539K -497K -464K -875K -58.17M -894K -2.31M -28.72M -2.31M -2.26M -100M EV / Sales 2022
29.3x
EV / Sales 2023 7.46x
Free-Float
61.98%
Yield 2022 *
-
Yield 2023 -
1 day+3.14%
1 week-0.21%
Current month+2.58%
1 month+7.56%
3 months+82.39%
6 months+155.50%
Current year+270.82%
1 week 1.7
Extreme 1.702
2.3
1 month 1.64
Extreme 1.64
2.4
Current year 0.52
Extreme 0.52
3.27
1 year 0.51
Extreme 0.514
4.4
3 years 0.2
Extreme 0.203
5.52
5 years 0.2
Extreme 0.203
19.4
10 years 0.2
Extreme 0.203
31.5
Manager TitleAgeSince
Chief Operating Officer 67 01/01/2006
Chief Executive Officer 73 -
Chief Executive Officer 50 29/12/2023
Director TitleAgeSince
Chairman 73 16/12/2024
Director/Board Member 67 01/01/2006
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
+3.14%-0.21%-34.73%-53.51% 6.07M
-0.50%+12.23%+119.83%+132.75% 4.83B
+2.10%+22.08%+81.51%+211.95% 3.35B
+3.58%+1.07%-26.99%-40.89% 1.96B
-0.94%+7.67%+149.11%-42.95% 1.9B
+1.60%+11.84%+52.26%+233.87% 1.49B
+2.73%+22.88%+158.70%-48.72% 917M
+8.75%+9.53%-7.73%+46.75% 842M
+1.59%-6.24%-37.37%-18.86% 466M
+17.16%-14.34%+16.56% - 435M
Average +3.92%+8.23%+47.12%+46.71% 1.62B
Weighted average by Cap. +1.87%+11.60%+79.58%+96.73%

Financials

2022 2023
Net sales 3.37M 347K 304K 280K 262K 493K 32.8M 504K 1.3M 16.19M 1.3M 1.27M 56.67M 2.95M 304K 266K 245K 229K 432K 28.69M 441K 1.14M 14.16M 1.14M 1.11M 49.57M
Net income -29.77M -3.07M -2.68M -2.48M -2.31M -4.36M -290M -4.46M -11.5M -143M -11.51M -11.26M -501M -32.52M -3.35M -2.93M -2.7M -2.53M -4.76M -317M -4.87M -12.57M -156M -12.58M -12.3M -547M
Net Debt -44.89M -4.62M -4.05M -3.73M -3.49M -6.57M -437M -6.72M -17.35M -216M -17.36M -16.98M -755M -13.4M -1.38M -1.21M -1.11M -1.04M -1.96M -130M -2.01M -5.18M -64.42M -5.18M -5.07M -225M
Logo 2cureX AB
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Employees
14
Date Price Change Volume
29/06/26 SEK 1.906 +3.14% 125,333
26/06/26 SEK 1.848 +1.43% 5,650
25/06/26 SEK 1.822 -3.19% 5,743
24/06/26 SEK 1.882 +0.11% 28,169
23/06/26 SEK 1.880 -5.81% 23,945
  1. Stock Market
  2. Stocks
  3. 2CUREX Stock